Nazanin Falconer

Nazanin Falconer

Auto-generated profile, based on publicly available information

Nazanin Falconer

School of Pharmacy, University of Queensland, Brisbane, Australia

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2018 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
NFNazanin Falconer
Nazanin Falconer
MBMichael Barras
Michael Barras
NCNeil Cottrell
Neil Cottrell

15 February 2014 in American Journal of Health-System Pharmacy
Verified
Journal Article
Closed access
NFNazanin Falconer
Nazanin Falconer
SNSanjoy Nand
Sanjoy Nand
DLDoreen Liow
Doreen Liow
AJAaron Jackson
Aaron Jackson
MSMary Seddon
Mary Seddon
A software-based tool to help prioritize inpatients for adverse drug event (ADE) prevention initiatives is described. The clinical pharmacy department of a New Zealand hospital developed the Assessment of Risk Tool (ART), an application for monitoring prespecified clinical "flags" (some derived from the Institute for Healthcare Improvement's ADE trigger tool) for high-risk medication use and other ADE risk factors. The ART permits ADE risk assessment in virtual real time (i.e., medication-use data and other clinical information are updated multiple times daily). Each of the 38 flags captured by the ART is assigned a weighted score; the item scores are summed to provide a total ART score indicating low, medium, or high ADE risk, and patients are prioritized by the ART score for pharmacist interventions such as clinical review and discharge coordination. In the first 18 months after ART implementation, the average number of patients receiving medication reconciliation each month increased from 280 to 500. During one 8-month period, 765 high-risk patients were prioritized for discharge services and 526 medication errors (MEs) were prevented, including 174 errors deemed to pose a threat of moderate-to-major patient harm. The tool has been well received by clinicians and has generated interest among other New Zealand hospitals. By facilitating the identification and monitoring of patients at high risk for MEs and ADEs, the ART has enabled one hospital's clinical pharmacists to conduct interventions such as medication reconciliation and clinical review in a more timely and targeted manner.

11 October 2018 in European Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
NFNazanin Falconer
Nazanin Falconer
MBMichael Barras
Michael Barras
JMJennifer Helen Martin
Jennifer Helen Martin
NCNeil Cottrell
Neil Cottrell

23 August 2024 in Journal of Medical Systems
Verified
Journal Article
Open access
PDF file
SMSreyon Murthi
Sreyon Murthi
NMNataly Dominica Martini
Nataly Dominica Martini
NFNazanin Falconer
Nazanin Falconer
SSShane Scahill
Shane Scahill
: The purpose of this scoping review is to identify and evaluate studies that examine the effectiveness and implementation strategies of Electronic Health Record (EHR)-integrated digital technologies aimed at improving medication-related outcomes and promoting health equity among hospitalised adults. Using the Consolidated Framework for Implementation Research (CFIR), the implementation methods and outcomes of the studies were evaluated, as was the assessment of methodological quality and risk of bias. Searches through Medline, Embase, Web of Science, and CINAHL Plus yielded 23 relevant studies from 1,232 abstracts, spanning 11 countries and from 2008 to 2022, with varied research designs. Integrated digital tools such as alert systems, clinical decision support systems, predictive analytics, risk assessment, and real-time screening and surveillance within EHRs demonstrated potential in reducing medication errors, adverse events, and inappropriate medication use, particularly in older patients. Challenges include alert fatigue, clinician acceptance, workflow integration, cost, data integrity, interoperability, and the potential for algorithmic bias, with a call for long-term and ongoing monitoring of patient safety and health equity outcomes. This review, guided by the CFIR framework, highlights the importance of designing health technology based on evidence and user-centred practices. Quality assessments identified eligibility and representativeness issues that affected the reliability and generalisability of the findings. This review also highlights a critical research gap on whether EHR-integrated digital tools can address or worsen health inequities among hospitalised patients. Recognising the growing role of Artificial Intelligence (AI) and Machine Learning (ML), this review calls for further research on its influence on medication management and health equity through integration of EHR and digital technology.

19 August 2023 in American Journal of Infection Control
Verified
Journal Article
Open access
DKDipti Khatri
Dipti Khatri
CFChristopher Freeman
Christopher Freeman
NFNazanin Falconer
Nazanin Falconer
SCSoraia de Camargo Catapan
Soraia de Camargo Catapan
LGLeonard C. Gray
Leonard C. Gray
DPDavid L. Paterson
David L. Paterson
Antimicrobial stewardship (AMS) guidelines advocate for the use of antibiograms (cumulative antimicrobial susceptibility test data) as a tool to guide empirical antibiotic prescribing and inform local treatment guidelines. The objective of this review is to evaluate the effectiveness of antibiograms as an intervention to optimize antimicrobial prescribing and patient outcomes. Embase, PubMed, CINAHL, and International Pharmacy Abstracts (IPA) databases were searched from inception until September 2022, to identify studies of antibiogram-related interventions in all health care settings. The National Institutes of Health Quality Assessment Tools were used to assess the methodological quality of the included studies. Of the 37 included studies, the majority of studies were conducted in the United States (n = 25) and in hospital settings (n = 27). All interventions were multifaceted and in 26 (70%) studies, facility-specific antibiograms could be considered as an integral component of the interventions. A positive impact on antibiotic consumption trends (17 studies), appropriateness of prescribing (16 studies), and cost of treatment (6 studies) was found, with minimal evidence for improvement in mortality, hospitalization, and resistance profiles. Due to the heterogeneity in study designs and outcomes, a meta-analysis was not performed. AMS interventions including antibiograms may improve antibiotic use, appropriateness, and costs. Multifaceted interventions were often used, which precludes drawing conclusions about the effectiveness of antibiograms alone as an AMS tool.

1 October 2019 in Research in Social and Administrative Pharmacy
Verified
Journal Article
Closed access
NFNazanin Falconer
Nazanin Falconer
MBMichael Barras
Michael Barras
NCNeil Cottrell
Neil Cottrell